• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SGI-DNA launches cell engineering services

SGI-DNA launches cell engineering services

December 15, 2015
CenterWatch Staff

SGI-DNA, a Synthetic Genomics Inc. (SGI) company based in La Jolla, Calif., has launched a suite of cell engineering services for generation of custom mammalian cell lines for research use.

Cell lines developed using the service are appropriate for the expression of novel proteins as well as a variety of functional studies, including cell-based assays for compound screening.

The introduction of the service provides research laboratories access to all aspects of SGI’s extensive cell engineering experience for design, development and generation of custom cell lines with novel properties. Unique to the service is the SGI Archetype software that offers extensive genomic databases, proprietary algorithms, and bioinformatics tool sets to aid design.

For each project, SGI-DNA’s scientific staff collaborates with clients and partners to provide expert insight and develop innovative strategies that leverage their advanced technologies. To ensure reliable data, cell lines developed by SGI-DNA are verified by sequencing and further validated upon customer request. The process results in a fully optimized cell engineering approach designed to alleviate challenges, such as variable protein expression, low product yields, and protein instability.

“SGI’s research efforts have greatly expanded our mammalian cell engineering capabilities. This has allowed us to develop innovative approaches to address extremely complex mammalian cell engineering challenges in our collaborations with leading biopharmaceutical partners,” said Sean Stevens, SGI’s leader of mammalian synthetic biology. “Through SGI-DNA, we can now offer precise cell engineering services which take advantage of our unique combination of proprietary sequence databases, state-of-the-art bioinformatics, and experimental know-how.”

Key advantages of SGI-DNA’s cell engineering services include: generation of novel genotypes through mutations at multiple genomic loci; creation of complex multigenic DNA constructs; combination of expression modulation, various reporter genes, generation of knock-in and knock-out cell lines; minimization of off-target risks through the use of proprietary bioinformatics algorithms; and expression of virtually any gene sequence with selection markers of one’s choice.

A key technology behind SGI-DNA’s cell engineering services is the Gibson Assembly method, developed in 2009 by Dan Gibson and his colleagues at the J. Craig Venter Institute along with Synthetic Genomics. In 2010, that well-established approach was used to create the first fully synthetic cell.

Since the commercial introduction of the Gibson Assembly method to the life science community by SGI-DNA, it has become a mainstay in many synthetic biology laboratories and has attracted interest from the academic and commercial life sciences communities.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing